Extended Data Fig. 2: Effect of dapagliflozin on the hierarchical composite outcome in sensitivity model 1. | Nature Medicine

Extended Data Fig. 2: Effect of dapagliflozin on the hierarchical composite outcome in sensitivity model 1.

From: A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials

Extended Data Fig. 2

Win statistics are two-sided. Models are stratified by diabetes status (and by trial in the pooled dataset). Adjustments are not made for multiple comparisons. The exact p-values were 0.000002 in the pooled dataset and 0.00005 in DELIVER. CI, confidence interval; DAPA-HF, Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; DELIVER, Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure trial; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease.

Back to article page